Clinical Applications and Perspectives of Circulating Tumor DNA in Gastric Cancer

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2024 Jan 6

PMID 38184573

Authors

Jing-Han Li

Dan-Ying Zhang

Ji-Min Zhu

Ling Dong

Affiliations

Soon will be listed here.

Abstract

Gastric cancer remains a leading cause of cancer-related death worldwide, largely due to inadequate screening methods, late diagnosis, and limited treatment options. Liquid biopsy has emerged as a promising non-invasive approach for cancer screening and prognosis by detecting circulating tumor components like circulating tumor DNA (ctDNA) in the blood. Numerous gastric cancer-specific ctDNA biomarkers have now been identified. CtDNA analysis provides insight into genetic and epigenetic alterations in tumors, holding promise for predicting treatment response and prognosis in gastric cancer patients. This review summarizes current research on ctDNA biology and detection technologies, while highlighting clinical applications of ctDNA for gastric cancer diagnosis, prognosis, and guiding treatment decisions. Current challenges and future perspectives for ctDNA analysis are also discussed.

Citing Articles

Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial.

Wu J, Zhang S, Yu S, An G, Wang Y, Yu Y Nat Commun. 2024; 15(1):8876.

PMID: 39406730 PMC: 11480398. DOI: 10.1038/s41467-024-53109-4.

Emerging Therapeutic Targets and Future Directions in Advanced Gastric Cancer: A Comprehensive Review.

Ratti M, Orlandi E, Toscani I, Vecchia S, Anselmi E, Hahne J Cancers (Basel). 2024; 16(15).

PMID: 39123420 PMC: 11311890. DOI: 10.3390/cancers16152692.

Targeting HER2 in Gastroesophageal Adenocarcinoma: Molecular Features and Updates in Clinical Practice.

Bonomi M, Spada D, Baiocchi G, Celotti A, Brighenti M, Grizzi G Int J Mol Sci. 2024; 25(7).

PMID: 38612688 PMC: 11011631. DOI: 10.3390/ijms25073876.

References

Han J, Lv P, Yu J, Wu Y, Zhu X, Hong L . Circulating methylated MINT2 promoter DNA is a potential poor prognostic factor in gastric cancer. Dig Dis Sci. 2014; 59(6):1160-8. DOI: 10.1007/s10620-013-3007-0. View

Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, Dive C . How liquid biopsies can change clinical practice in oncology. Ann Oncol. 2019; 30(10):1580-1590. DOI: 10.1093/annonc/mdz227. View

Wu R, Li Q, Wu F, Shi C, Chen Q . Comprehensive Analysis of Related to Peritoneal Metastasis by Whole Exome Sequencing in Gastric Cancer. Onco Targets Ther. 2020; 13:3335-3346. PMC: 7183333. DOI: 10.2147/OTT.S244351. View

Bernal C, Aguayo F, Villarroel C, Vargas M, Diaz I, Ossandon F . Reprimo as a potential biomarker for early detection in gastric cancer. Clin Cancer Res. 2008; 14(19):6264-9. DOI: 10.1158/1078-0432.CCR-07-4522. View

Rosati G, Ferrara D, Manzione L . New perspectives in the treatment of advanced or metastatic gastric cancer. World J Gastroenterol. 2009; 15(22):2689-92. PMC: 2695882. DOI: 10.3748/wjg.15.2689. View

Xu S, Lou F, Wu Y, Sun D, Zhang J, Chen W . Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients. Cancer Lett. 2015; 370(2):324-31. PMC: 7495502. DOI: 10.1016/j.canlet.2015.11.005. View

Pasechnikov V, Chukov S, Fedorov E, Kikuste I, Leja M . Gastric cancer: prevention, screening and early diagnosis. World J Gastroenterol. 2014; 20(38):13842-62. PMC: 4194567. DOI: 10.3748/wjg.v20.i38.13842. View

Takahashi T, Saikawa Y, Kitagawa Y . Gastric cancer: current status of diagnosis and treatment. Cancers (Basel). 2013; 5(1):48-63. PMC: 3730304. DOI: 10.3390/cancers5010048. View

Li W, Zhang X, Lu X, You L, Song Y, Luo Z . 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers. Cell Res. 2017; 27(10):1243-1257. PMC: 5630683. DOI: 10.1038/cr.2017.121. View

10.

Feng Q, Yang Z, Zhang J, Tang J . Comparison of direct sequencing and amplification refractory mutation system for detecting epidermal growth factor receptor mutation in non-small-cell lung cancer patients: a systematic review and meta-analysis. Oncotarget. 2017; 8(35):59552-59562. PMC: 5601754. DOI: 10.18632/oncotarget.19110. View

11.

Kato S, Okamura R, Baumgartner J, Patel H, Leichman L, Kelly K . Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma. Clin Cancer Res. 2018; 24(24):6248-6256. PMC: 6384095. DOI: 10.1158/1078-0432.CCR-18-1128. View

12.

Gupta N, Bansal A, Wani S, Gaddam S, Rastogi A, Sharma P . Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis. Gastrointest Endosc. 2011; 74(3):610-624.e2. DOI: 10.1016/j.gie.2011.05.001. View

13.

Lui Y, Chik K, Chiu R, Ho C, Lam C, Lo Y . Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem. 2002; 48(3):421-7. View

14.

Ren J, Lu P, Zhou X, Liao Y, Liu X, Li J . Genome-Scale Methylation Analysis of Circulating Cell-Free DNA in Gastric Cancer Patients. Clin Chem. 2021; 68(2):354-364. DOI: 10.1093/clinchem/hvab204. View

15.

Lu X, Yu J, Ying L, Han J, Wang S, Yu Q . Stepwise cumulation of RUNX3 methylation mediated by Helicobacter pylori infection contributes to gastric carcinoma progression. Cancer. 2012; 118(22):5507-17. DOI: 10.1002/cncr.27604. View

16.

Lan Y, Chen M, Fang W, Hsieh C, Lin C, Jhang F . Clinical relevance of cell-free DNA in gastrointestinal tract malignancy. Oncotarget. 2016; 8(2):3009-3017. PMC: 5356859. DOI: 10.18632/oncotarget.13821. View

17.

Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S . Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005; 102(45):16368-73. PMC: 1283450. DOI: 10.1073/pnas.0507904102. View

18.

Pu W, Zhang R, Xiao L, Wu Y, Gong W, Lv X . Prediction of cancer progression in a group of 73 gastric cancer patients by circulating cell-free DNA. BMC Cancer. 2016; 16(1):943. PMC: 5148873. DOI: 10.1186/s12885-016-2977-7. View

19.

Liu Z, Wang Z, Jia E, Ouyang T, Pan M, Lu J . Analysis of genome-wide in cell free DNA methylation: progress and prospect. Analyst. 2019; 144(20):5912-5922. DOI: 10.1039/c9an00935c. View

20.

Huang Y, Yu J, Kang W, Ma Z, Ye X, Tian S . Significance of Serum Pepsinogens as a Biomarker for Gastric Cancer and Atrophic Gastritis Screening: A Systematic Review and Meta-Analysis. PLoS One. 2015; 10(11):e0142080. PMC: 4640555. DOI: 10.1371/journal.pone.0142080. View